Lonvoguran ziclumeran

Lonvoguran ziclumeran (also known as lonvo-z) is an investigational gene therapy being developed to treat hereditary angioedema. It is a CRISPR-based gene therapy, and, if approved by the FDA, it would be the first example of an approved, in vivo, CRISPR-based gene therapy. The drug is being developed by Intellia Therapeutics and was initially known by the investigational drug name NTLA-2002.[1][2][3]

References

  1. ↑ Markman, Jon. "CRISPR Breakthrough Brings First In-Body Cure With Lonvo-Z". Forbes. Forbes. Retrieved 1 June 2026.
  2. ↑ "Intellia is seeking FDA approval for what could be the first in vivo CRISPR gene editing therapy". Quartz (publication). 27 April 2026. Retrieved 1 June 2026.
  3. ↑ "Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy". Nature (journal). 18 May 2026. doi:10.1038/s41587-026-03154-9. Retrieved 1 June 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.